Allergy and Clinical Immunology Unit, Antalya Education and Training Hospital, Antalya, Turkey.
Med Sci Monit. 2012 Mar;18(3):PI11-5. doi: 10.12659/msm.882504.
In this study we compare the Omalizumab treatment modality in the dynamics of cell apoptosis regulating molecules in both severe persistent asthma patients who had no other any allergic disease, newly diagnosed patients with allergic asthma, and healthy volunteers.
MATERIAL/METHODS: Severe persistent allergic asthma patients were subjected to measurement of serum soluble TRAIL (TNF-related apoptosis-inducing ligand) levels during the active disease phase and the stable phase which occurred 4 months after Omalizumab treatment. Serum sTRAIL concentrations were measured by a solid phase sandwich enzyme-linked immunosorbent assay. Concentration levels were compared with those of age- and sex-matched newly diagnosed patients with allergic asthma, and healthy controls. All assays were carried out in duplicate. Total serum IgE levels, antinuclear antibody (ANA), rheumatoid factor (RF), hepatitis markers, C3, C4 and eosinophil levels were evaluated in all patients.
ANA, RF, hepatitis markers were negative in all patients. Complement 3 and 4 levels were normal in all patients. Prick tests in all patients were detected in mite and grass allergy. These results correlated with specific IgE. There were no differences between the healthy controls, newly diagnosed allergic asthma patients, and non-treated severe persistent allergic asthma patients during the active phase. Interestingly, the levels in variances of the patients who had the effective omalizumab treatment were significantly lower than the healthy controls, while the mean values were not statistically significant.
Our study gives a different perspective on severe persistent allergic asthma and omalizumab treatment efficacy at the cell apoptosis-linked step by the serum sTRAIL levels.
本研究比较了奥马珠单抗治疗模式对无其他过敏疾病的重度持续性哮喘患者、新诊断的过敏性哮喘患者和健康志愿者中细胞凋亡调节分子的动态变化。
材料/方法：重度持续性过敏性哮喘患者在疾病活动期和奥马珠单抗治疗后 4 个月的稳定期测量血清可溶性 TRAIL（TNF 相关凋亡诱导配体）水平。采用固相夹心酶联免疫吸附试验测定血清 sTRAIL 浓度。将浓度与年龄和性别匹配的新诊断的过敏性哮喘患者和健康对照组进行比较。所有检测均重复进行。所有患者均评估总血清 IgE 水平、抗核抗体（ANA）、类风湿因子（RF）、肝炎标志物、C3、C4 和嗜酸性粒细胞水平。
所有患者的 ANA、RF、肝炎标志物均为阴性。所有患者的补体 3 和 4 水平均正常。所有患者的划痕试验均检测到螨和草过敏。这些结果与特异性 IgE 相关。在疾病活动期，健康对照组、新诊断的过敏性哮喘患者和未经治疗的重度持续性过敏性哮喘患者之间没有差异。有趣的是，接受有效奥马珠单抗治疗的患者的变异水平明显低于健康对照组，而平均值无统计学意义。
我们的研究通过血清 sTRAIL 水平从细胞凋亡相关步骤提供了对重度持续性过敏性哮喘和奥马珠单抗治疗效果的不同视角。
